<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275834</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00005514</org_study_id>
    <secondary_id>R01DK067352</secondary_id>
    <secondary_id>1R01DK067352</secondary_id>
    <nct_id>NCT00275834</nct_id>
  </id_info>
  <brief_title>Zonisamide for Weight Reduction in Obese Adults</brief_title>
  <official_title>Zonisamide for Weight Reduction in Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to assess long-term weight loss efficacy of zonisamide
      relative to placebo in obese patients prescribed a dietary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This RCT compares two doses of zonisamide and placebo for one year. A total of 225 subjects
      are randomly assigned to one of the three treatment interventions at Duke University Medical
      Centre. The primary outcome measure is change in body weight in kilograms. Secondary outcomes
      include changes in waist circumference, glycaemic and inflammatory markers, lipids, food
      craving, hunger and satiety, quality of life, blood pressure and heart rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint was weight loss at 1-year, Month-12 weight minus baseline weight, in kilograms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of Patients With 5% Weight Loss</measure>
    <time_frame>1 year</time_frame>
    <description>These were the proportions of patients losing 5% or more weight at 1-year relative to baseline. The measures were modeled with logistic regressions that included the three-level group proxy and a baseline weight covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Patients With 10% Weight Loss</measure>
    <time_frame>1 year</time_frame>
    <description>This outcomes measure followed the same principles at measurement of proportions of patients with 5% weight loss described elsewhere.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>1 year</time_frame>
    <description>Analyses was based on intent-to-treat ANCOVA. Difference scores from baseline to endpoint (Month-12) for each measure were regressed on the three-level proxy denoting group while controlling for the baseline value of the same measure. Contrasts were subsequently estimated in models, which had a significant overall treatment effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers (CRP)</measure>
    <time_frame>1 year</time_frame>
    <description>C reactive Protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipids</measure>
    <time_frame>baseline, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by HADS_D</measure>
    <time_frame>1 year</time_frame>
    <description>Hospital Anxiety and Depression Scale - Depression (HADS-D) The HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>Baseline, 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zonisamide 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zonisamide 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide</intervention_name>
    <description>zonisamide 400 mg, 200 mg, or placebo</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Age 18-65 years; BMI 30-50

        Exclusion Criteria:

        Secondary obesity; Significant cardiovascular disease; Stroke, seizure disorder or other
        significant neurological disease; Significant liver or gallbladder disease; Significant
        renal disease or history of kidney stones; HIV positive status; Diabetes mellitus;
        Untreated or unstable hypothyroidism Malignancy in the past 5 years; Concomitant
        medications that cause significant weight gain or weight loss; Concomitant use of
        prescription or OTC weight loss medications; Had bariatric surgery or planning surgery in
        the next 1 year; Weight change of more than 4 kg in the past 3 months; Suicidal subjects;
        Major depression in the past 6 months; History of psychosis, bipolar disorder, or severe
        personality disorders; Subjects taking antipsychotics or mood stabilisers; Alcohol or
        substance abuse in the past 6 months; Currently taking zonisamide or other antiepileptic
        drugs; History of hypersensitivity to zonisamide or sulfonamides; Pregnant or planning
        pregnancy in the next year, or breastfeeding; Severe physical disability; Current
        participation in a commercial weight loss program or planning to participate; Currently
        following low-carbohydrate, high protein, high fat diet; Use of investigational medications
        or devices (current or past 4 weeks)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kishore M Gadde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Centre</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gadde KM, Kopping MF, Wagner HR 2nd, Yonish GM, Allison DB, Bray GA. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med. 2012 Nov 12;172(20):1557-64. doi: 10.1001/2013.jamainternmed.99.</citation>
    <PMID>23147455</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2006</study_first_posted>
  <results_first_submitted>December 10, 2012</results_first_submitted>
  <results_first_submitted_qc>December 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2013</results_first_posted>
  <last_update_submitted>November 15, 2016</last_update_submitted>
  <last_update_submitted_qc>November 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity treatment</keyword>
  <keyword>weight loss</keyword>
  <keyword>antiobesity drugs</keyword>
  <keyword>zonisamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at Duke University Medical Center between 2006 and 2011.</recruitment_details>
      <pre_assignment_details>Participants are considered to have completed the study if they returned for final study visit. The number completed represents participants who stayed on study drug during the trial plus participants who discontinued study drug during the trial but continued to be followed by study team and completed the final visit assessments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Zonisamide 100 mg and placebo capsules were prepared in accordance with Good Manufacturing Practice (GMP) guidelines in Duke Compounding Facility with active pharmaceutical ingredient (Sochinaz SA, Switzerland, distributed by Bachem Americas, King of Prussia, Pennsylvania) plus dextrose as an inactive ingredient. Identical-looking placebo capsules contained dextrose.
Each capsule contained zonisamide 100 mg or placebo, with patients and study staff blinded to contents. Dose was gradually titrated upward as follows: 1 capsule for 15 days, 2 during days 16-30, 3 capsules during days 31-45, and 4 from day 46 onward. The entire dose was taken at night. Blinded dose reduction was allowed and dose increase could be withheld. Patients had the option to discontinue the drug and remain in the study receiving only diet and lifestyle counseling.</description>
        </group>
        <group group_id="P2">
          <title>Zonisamide 200 mg</title>
          <description>Dosing of matching placebo was identical.</description>
        </group>
        <group group_id="P3">
          <title>Zonisamide 400 mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Study While on Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Zonisamide 200 mg</title>
        </group>
        <group group_id="B3">
          <title>Zonisamide 400 mg</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="225"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="10.3"/>
                    <measurement group_id="B2" value="44.2" spread="10.1"/>
                    <measurement group_id="B3" value="42.3" spread="10.0"/>
                    <measurement group_id="B4" value="43.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Weight</title>
        <description>The primary endpoint was weight loss at 1-year, Month-12 weight minus baseline weight, in kilograms.</description>
        <time_frame>1 year</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Zonisamide 200 mg</title>
          </group>
          <group group_id="O3">
            <title>Zonisamide 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>The primary endpoint was weight loss at 1-year, Month-12 weight minus baseline weight, in kilograms.</description>
          <population>intent-to-treat</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-5.8" upper_limit="-2.3"/>
                    <measurement group_id="O2" value="-4.4" lower_limit="-6.1" upper_limit="-2.6"/>
                    <measurement group_id="O3" value="-7.3" lower_limit="-9.0" upper_limit="-5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Patients With 5% Weight Loss</title>
        <description>These were the proportions of patients losing 5% or more weight at 1-year relative to baseline. The measures were modeled with logistic regressions that included the three-level group proxy and a baseline weight covariate.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Zonisamide 200 mg</title>
          </group>
          <group group_id="O3">
            <title>Zonisamide 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Proportions of Patients With 5% Weight Loss</title>
          <description>These were the proportions of patients losing 5% or more weight at 1-year relative to baseline. The measures were modeled with logistic regressions that included the three-level group proxy and a baseline weight covariate.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Patients With 10% Weight Loss</title>
        <description>This outcomes measure followed the same principles at measurement of proportions of patients with 5% weight loss described elsewhere.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Zonisamide 200 mg</title>
          </group>
          <group group_id="O3">
            <title>Zonisamide 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Proportions of Patients With 10% Weight Loss</title>
          <description>This outcomes measure followed the same principles at measurement of proportions of patients with 5% weight loss described elsewhere.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Analyses was based on intent-to-treat ANCOVA. Difference scores from baseline to endpoint (Month-12) for each measure were regressed on the three-level proxy denoting group while controlling for the baseline value of the same measure. Contrasts were subsequently estimated in models, which had a significant overall treatment effect.</description>
        <time_frame>1 year</time_frame>
        <population>intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Zonisamide 200 mg</title>
          </group>
          <group group_id="O3">
            <title>Zonisamide 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Analyses was based on intent-to-treat ANCOVA. Difference scores from baseline to endpoint (Month-12) for each measure were regressed on the three-level proxy denoting group while controlling for the baseline value of the same measure. Contrasts were subsequently estimated in models, which had a significant overall treatment effect.</description>
          <population>intent-to-treat</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" lower_limit="-6.6" upper_limit="-3.1"/>
                    <measurement group_id="O2" value="-6.1" lower_limit="-7.8" upper_limit="-4.3"/>
                    <measurement group_id="O3" value="-8.5" lower_limit="-10.2" upper_limit="-6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers (CRP)</title>
        <description>C reactive Protein (CRP)</description>
        <time_frame>1 year</time_frame>
        <population>Participants who had CRP testing completed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Zonisamide 200 mg</title>
          </group>
          <group group_id="O3">
            <title>Zonisamide 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Markers (CRP)</title>
          <description>C reactive Protein (CRP)</description>
          <population>Participants who had CRP testing completed</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.523" spread="0.064"/>
                    <measurement group_id="O2" value="0.536" spread="0.06"/>
                    <measurement group_id="O3" value="0.443" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipids</title>
        <time_frame>baseline, 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Zonisamide 100 mg and placebo capsules were prepared in accordance with Good Manufacturing Practice (GMP) guidelines in Duke Compounding Facility with active pharmaceutical ingredient (Sochinaz SA, Switzerland, distributed by Bachem Americas, King of Prussia, Pennsylvania) plus dextrose as an inactive ingredient. Identical-looking placebo capsules contained dextrose.
Each capsule contained zonisamide 100 mg or placebo, with patients and study staff blinded to contents. Dose was gradually titrated upward as follows: 1 capsule for 15 days, 2 during days 16-30, 3 capsules during days 31-45, and 4 from day 46 onward. The entire dose was taken at night. Blinded dose reduction was allowed and dose increase could be withheld. Patients had the option to discontinue the drug and remain in the study receiving only diet and lifestyle counseling.</description>
          </group>
          <group group_id="O2">
            <title>Zonisamide 200 mg</title>
            <description>Dosing of matching placebo was identical.</description>
          </group>
          <group group_id="O3">
            <title>Zonisamide 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipids</title>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-7.2" upper_limit="3.4"/>
                    <measurement group_id="O2" value="4.1" lower_limit="-1.0" upper_limit="9.2"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-5.0" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-6.7" upper_limit="2.7"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-2.8" upper_limit="6.3"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-4.7" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.7" upper_limit="4.3"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-0.3" upper_limit="3.2"/>
                    <measurement group_id="O3" value="3.4" lower_limit="1.7" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" lower_limit="-22.6" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-10.1" upper_limit="11.5"/>
                    <measurement group_id="O3" value="-11.7" lower_limit="-22.2" upper_limit="-1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by HADS_D</title>
        <description>Hospital Anxiety and Depression Scale - Depression (HADS-D) The HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Zonisamide 200 mg</title>
          </group>
          <group group_id="O3">
            <title>Zonisamide 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by HADS_D</title>
          <description>Hospital Anxiety and Depression Scale - Depression (HADS-D) The HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="1.54" upper_limit="2.70"/>
                    <measurement group_id="O2" value="2.76" lower_limit="2.18" upper_limit="3.33"/>
                    <measurement group_id="O3" value="1.95" lower_limit="1.38" upper_limit="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure</title>
        <time_frame>Baseline, 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Zonisamide 100 mg and placebo capsules were prepared in accordance with Good Manufacturing Practice (GMP) guidelines in Duke Compounding Facility with active pharmaceutical ingredient (Sochinaz SA, Switzerland, distributed by Bachem Americas, King of Prussia, Pennsylvania) plus dextrose as an inactive ingredient. Identical-looking placebo capsules contained dextrose.
Each capsule contained zonisamide 100 mg or placebo, with patients and study staff blinded to contents. Dose was gradually titrated upward as follows: 1 capsule for 15 days, 2 during days 16-30, 3 capsules during days 31-45, and 4 from day 46 onward. The entire dose was taken at night. Blinded dose reduction was allowed and dose increase could be withheld. Patients had the option to discontinue the drug and remain in the study receiving only diet and lifestyle counseling.</description>
          </group>
          <group group_id="O2">
            <title>Zonisamide 200 mg</title>
            <description>Dosing of matching placebo was identical.</description>
          </group>
          <group group_id="O3">
            <title>Zonisamide 400 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Pressure</title>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-2.9" upper_limit="1.6"/>
                    <measurement group_id="O2" value="-4.4" lower_limit="-6.7" upper_limit="-2.1"/>
                    <measurement group_id="O3" value="-1.9" lower_limit="-4.1" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-3.2" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-3.6" lower_limit="-5.3" upper_limit="-2.0"/>
                    <measurement group_id="O3" value="-3.9" lower_limit="-5.5" upper_limit="-2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1-year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Zonisamide 200 mg</title>
        </group>
        <group group_id="E3">
          <title>Zonisamide 400 mg</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Altered taste</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal problems</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired concentration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Impaired memory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety related</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Depression related</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kishore Gadde</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-668-0208</phone>
      <email>kishore.gadde@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

